Vimarsana
Biggest News Aggregation in the World

Page 45 - Roivant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roivant Sciences Today - Breaking & Trending Today

Doug Burgum, Mike Pence and Vivek Ramaswamy up next in Exeter Town Hall forums - Vimarsana News

Doug Burgum, Mike Pence and Vivek Ramaswamy up next in Exeter Town Hall forums

Gov. Doug Burgum's Exeter town hall is Friday, 10 a.m.; VP Mike Pence is Friday at 3 p.m. and businessman Vivek Ramaswamy is Saturday at 10 a.m.

Source: yahoo.com
'Own What You Say': Sean Hannity Blasts 2024 Hopeful Vivek Ramaswamy in Tense Exchange - Vimarsana News

'Own What You Say': Sean Hannity Blasts 2024 Hopeful Vivek Ramaswamy in Tense Exchange

Sean Hannity and Vivek Ramaswamy got into a tense dispute after the Fox News personality addressed claims made by the 2024 hopeful in a heated segment.

Strategic Collaborations and Innovation Drive Next Generation Drug Conjugates Market: North America Takes the Lead in This Rapidly Growing Sector - Vimarsana News

Strategic Collaborations and Innovation Drive Next Generation Drug Conjugates Market: North America Takes the Lead in This Rapidly Growing Sector

/PRNewswire/ -- The "Next Generation Drug Conjugates Market: Distribution by Type of Targeting Ligand, Type of Payload, Type of Therapy, Route of...

Advancing Beyond Antibody Drug Conjugates: Next Generation - Vimarsana News

Advancing Beyond Antibody Drug Conjugates: Next Generation

Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The

Lilly's Mirikizumab Shows Long-Term Remission in Phase III Crohn's Trial - Vimarsana News

Lilly's Mirikizumab Shows Long-Term Remission in Phase III Crohn's Trial

More than 54% of patients treated with mirikizumab achieved clinical remission at 52 weeks versus 19.6% of those on placebo. Eli Lilly will submit a marketing application in Crohn’s disease to the FDA in 2024.